Eli Lilly and Co
This up-and-coming cancer treatment could be a $25 billion market opportunity — it’s already a hotbed for M&A
Skynesher | E+ | Getty Images Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a “massive opportunity.” It’s called targeted radiopharmaceutical therapy. It essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. RBC Capital Markets sees a $25 […]
Read More
A corner of the cancer therapy market is heating up—Here are the names investors need to know
There’s been a lot of attention lately on a corner of the oncology market called radiopharmaceuticals. The therapy seeks to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor. There are currently two products on the market from Novartis and a slew of clinical […]
Read More
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins
A patient injects herself with an insulin pen. Guido Krzikowski | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The rivalry between Eli Lilly and Novo Nordisk extends beyond a buzzy class of weight loss and diabetes drugs called GLP-1s. […]
Read More
JPMorgan states there is a new GLP-1 drug participant and its shares can rally 80%
Composition Therapeutics is an overlooked player in the GLP-1 current market, and could 1 working day boast a aggressive products and go up versus Eli Lilly and the like, according to JPMorgan. Analyst Hardik Parikh initiated research coverage on the clinical stage drug developer with an chubby rating and $65 value concentrate on, implying 82% […]
Read More
Eli Lilly stock hits new highs after a regulatory win in China. This is a big deal
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. The Nasdaq edged lower Tuesday, pulling back from record highs the session before. Jim Cramer described the market as overall “benign,” while the S & P 500 and Dow also […]
Read More
AstraZeneca targets $80 billion in total revenue by 2030 in ‘post-Covid era’
The Astrazeneca logo is pictured at the World Artificial Intelligence Conference 2021 in Shanghai, China, July 7, 2021. Costfoto | Future Publishing | Getty Images LONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. “We have […]
Read More
Roche says weight loss drug shows promising results in early trial
A logo at the Roche Holding AG headquarters in Basel, Switzerland, on Thursday, Feb. 1, 2024. Bloomberg | Getty Images Roche on Thursday said its experimental weight loss drug showed promising results in an early-stage trial, boosting the company’s bid to compete in the booming market for those treatments. The Swiss company joined a slate of […]
Read More
Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey says
Rebekah Carl poses with her prescription of Wegovy in New Columbia, Pennsylvania, U.S., November 13, 2023. Hannah Beier | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The use of a buzzy class of weight loss and diabetes medications is more common […]
Read More
People on Novo Nordisk’s Wegovy maintain weight loss for up to four years, study says
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Patients taking Novo Nordisk‘s obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis published Tuesday from the longest clinical trial to date […]
Read More
Google’s Demis Hassabis is the gentleman tasked with turning bleeding-edge AI investigate into income
Demis Hassabis is a celebrated identify in synthetic intelligence investigate. He is a chess learn and a neuroscientist. On Wall Avenue, he’s fewer regarded. That may perhaps not be genuine for very long. Hassabis is emerging as the encounter of Google’s mammoth AI effort and on Tuesday will consider the stage at the annual developer’s […]
Read More